Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial

Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of neuropathic pain. the investigators propose to study if addition of BTA extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).

Principal Investigator

  • Sean Mackey, M.D., Ph.D.

Stanford Investigator(s)

  • Ian Carroll, MD, MS

CONTACT INFORMATION

Primary Contact:
Charlie Wang
(650) 723-8250